LAG3 and cancer: This field is rapidly evolving, with new agents targeting other inhibitory T-cell, such as Lymphocyte-activation gene 3 (LAG-3), T-cell immunoglobulin, and mucin domain-containing 3 (TIM-3), or T-cell immune receptor with immunoglobulin and ITIM domain (TIGIT), being developed to further improve the effectiveness of cancer immunotherapy.